Results 111 to 120 of about 44,923 (207)

The Dual Role of the Gut Microbiota in Cancer Chemoresistance

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Comparison between Microbiota and Cancer therapy. ABSTRACT Chemoresistance is one of the primary reasons that cancer chemotherapy fails to deliver successful treatment outcomes and contributes to poor overall survival rates for patients with cancer. New research has begun to shed light on the effects of the gut microbiome (GM).
Hamed Tahmasebi, Aisa Bahar, Meisam Khazaei, Mohammad Reza Arabestani   +3 more
wiley   +1 more source

Deep Learning Predicts Imminent Tumor Progression in Advanced Pancreatic Adenocarcinoma Using Serial CT Scans During Chemotherapy

MedComm, Volume 7, Issue 8, August 2026.
A spatiotemporal deep learning model combining serial CT scans and baseline clinical data predicts tumor progression at the next follow‐up visit in advanced PDAC. The model achieved robust performance across internal, external, and prospective cohorts (AUC: 0.74–0.77). This noninvasive approach enables earlier identification of imminent progression and
Jun Cheng, Yize Mao, Shuxiang Huang, Xiaotong Tan, Xiaoping Yi, Xiaoying Du, Qiulin Liu, Jianyao Zhou, Rong Huang, Weijie Chen, Rong Zhang, Lizhi Liu, Wufeng Xue, Ruobing Huang, Youhui Qian, Dong Ni, Wenjun Mao, Tao Qin, Shengping Li, Qiuxia Yang   +19 more
wiley   +1 more source

Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study

Nutrition in Clinical Practice, Volume 41, Issue 4, Page 1157-1165, August 2026.
Abstract Background Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
Pamela N. Klassen, Christina A. Kim, Jessica Kasnik, Michael B. Sawyer, Sunita Ghosh, Vickie Baracos, Vera C. Mazurak   +6 more
wiley   +1 more source

A Tale of Two Cell Lines: Characterization of Differential Efficacy of Small Molecule Drugs Cediranib and NU‐7441 on Primary Versus Metastatic Colorectal Cancer

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Colorectal cancer is recognized as one of the leading causes of cancer death amongst both sexes in the U.S. Despite rigorous screening, those diagnosed with colon cancer often face poor prognosis, and approximately 70% of affected patients will develop metastatic relapse. The investigation of colon carcinoma cell lines' genetic variability and
Josephine D. Tsang, Cai M. Roberts
wiley   +1 more source

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source

Quantum‐Capacitance Biosensing Enables Real‐Time Monitoring of Naxitamab for Therapeutic Response Stratification in Neuroblastoma

Small Science, Volume 6, Issue 8, August 2026.
Quantum‐capacitance biosensing enables real‐time monitoring of naxitamab in patient samples via laser‐fabricated electrodes and single‐point calibration. The proposed platform provides rapid and sensitive quantification, with the potential to enable therapeutic drug monitoring and patient stratification according to circulating naxitamab levels, while ...
Andy Bruno, Ruslán Alvarez‐Diduk, Paula Lara, Gabriel Maroli, Cristina Larrosa, Sandra López‐Miralles, Jaume Mora, Carlos J. Rodríguez‐Hernández, Arben Merkoçi   +8 more
wiley   +1 more source

Delivery of nano‐formulated drugs to solid tumours is selectively increased by co‐application of the vascular disrupting agent CA4P

British Journal of Pharmacology, Volume 183, Issue 16, Page 4663-4674, August 2026.
Background and purpose Nano‐formulated chemotherapeutics prolong systemic availability of drugs and can reduce systemic toxicity, but their accumulation in solid tumours is often limited and unpredictable. Broadly applicable strategies to selectively enhance tumour delivery are lacking.
Annabel Kitowski, Constanze Heise, Stefanie Sperling, Jasmin Hotz, Danica Bajic, Marina Rubey, Kathrin Klar, Georg Höfner, Julien Vollaire, Veronique Josserand, Jean‐Luc Coll, Oliver Thorn‐Seshold, Petar Marinković, Julia Thorn‐Seshold   +13 more
wiley   +1 more source

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

British Journal of Pharmacology, Volume 183, Issue 16, Page 4735-4760, August 2026.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen, Nils Johan Fredriksson, Michael Andresen, Jon Jonasson, Malin Lindqvist Appell, Henrik Gréen   +5 more
wiley   +1 more source

Irinotecan Modulates Immune Checkpoints in Neuroblastoma. [PDF]

Immunotargets Ther
Lapidus T, Zorde-Khvalevsky E, Jolani A, Goldstein G, Peled A.   +4 more
europepmc   +1 more source

Gasdermin‐Mediated Pyroptosis: Novel Strategies Against Colorectal Cancer

Cancer Science, Volume 117, Issue 8, Page 2064-2084, August 2026.
Pyroptosis is a double‐edged sword in colorectal cancer (CRC): chronic low‐grade pyroptosis promotes tumor progression, whereas acute induction of pyroptosis in cancer cells triggers antitumor immunity and enhances therapeutic response. Targeting gasdermin‐mediated pyroptosis represents a promising strategy for CRC treatment.
Kaibo Guo, Yuqian Feng, Jiamin Lu, Nuerbiye Abudurexiti, Xinlei Zhou, Mengfan Wei, Song Zheng   +6 more
wiley   +1 more source